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Oxidative stress is recognised as central in a range of neurological diseases including 
Amyotrophic lateral sclerosis (ALS), a disease characterised by fast progressing death of 
motor neurons in the brain and spinal cord. Cellular p thology includes cytosolic protein 
aggregates in motor neurons and glia of which potentially cytotoxic hyper-phosphorylated 
fragments of the Transactive response DNA Binding Protein 43 kDa (TDP-43) constitute a 
major component. This is closely associated with an additional loss of nuclear TDP-43 
expression indicating a “loss of function” mechanism, accelerating motor neuron (MN) loss. 
Furthermore, mutations in TDP-43 cause familial ALS and ALS-like disease in animal 
models. In this study, we investigated the role of glutathione (GSH) in modulating oxidative 
stress responses in TDP-43 pathology in motor neuro NSC-34 cells. Results demonstrate 
that depletion of GSH produces pathology similar to that of mutant TDP-43, including 
occurrence of cytosolic aggregates, TDP-43 phosphorylation and nuclear clearing of 
endogenous TDP-43. We also demonstrate that introducti n of mutant TDP-43A315T and 
silencing of endogenous TDP-43, but not overexpression of wild-type TDP-43, result in 
similar pathology, including depletion of intracellular GSH, possibly resulting from a 
decreased expression of a regulatory subunit of ɣ-glutamylcysteine ligase (GCLM), a rate 
limiting enzyme in GSH synthesis. Importantly, treament of mutant cells with GSH 
monoethyl ester (GSHe) that directly increases intracellular GSH and bypasses the need for 
GSH synthesis, protected against mutant-induced TDP-43 pathology, including reducing 
aggregate formation, nuclear clearance, reactive oxygen species (ROS) production and cell 
death. Our data strongly suggest that oxidative stres  is central to TDP-43 pathology and may 
result from a loss of function affecting GSH synthesis and that treatments directly aimed at 
restoring cellular GSH content may be beneficial in preventing cell death in TDP-43-

































Cytoplasmic accumulation of TDP-43 is a hallmark feature of many neurodegenerative 
disorders including Amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative condition 
characterised by a progressive death of upper and lower motor neurons (MNs) rapidly leading 
to muscle paralysis and death within a few years of diagnosis (Turner et al., 2013; Kwong et 
al., 2007). There is no cure or effective treatment available. ALS is either familial, with a 
predominantly autosomal dominant inheritance pattern, or sporadic (constituting 
approximately 90% of all cases), with no identifiable genetic cause (Robberecht and Philips, 
2013). Cellular pathology include protein aggregation, mitochondrial dysfunction, increased 
content of reactive oxygen species (ROS) and glutamate- ediated excitotoxicity (Rothstein 
2009). 
Histopathologically, a vast majority of ALS cases di play cytoplasmic protein inclusions 
containing the protein Transactive response DNA Binding Protein 43 kDa (TDP-43), a DNA- 
and RNA-binding protein encoded by the TAR DNA Binding Protein (TARDBP) gene. TDP-
43 is predominately localised to the nucleus where it participates in regulating transcription 
(Bose et al., 2008), but is also found in the cytosol where it has a regulatory role in translation 
and post-transcriptional modifications of pre-mRNA (Buratti and Baralle, 2008). Impaired 
protein processing leading to cytosolic aggregation of ubiquitinated and phosphorylated C-
terminally truncated fragments of TDP-43 are cellular characteristics of TDP-43 
proteinopathies (Kwong et al., 2007; Geser et al., 2008; Neumann et al., 2006). TPD-43 
pathology is present in 95% of all ALS cases and in about >60% of patients with 
frontotemporal dementia (Neumann et al., 2007; Mackenzie, 2007). 
Mutations in the TARDBP gene cause familial forms of ALS in humans and an ALS-like 















2008; Sreedharan et al., 2008; Stribl et al., 2014; Wegorzewska and Baloh, 2011). In contrast, 
over expression of human wild-type TDP-43 has recently been demonstrated not to result in 
an ALS phenotype in rodents (Mitchell t al. 2015).  
Even in the absence of genomic mutations, TDP-43 is found in cytosolic aggregates in 
neurons and astrocytes, and the pathology of these ca s is identical to those with a genetic 
background, strongly suggesting that exogenous factors induce pathogenic modifications of 
TDP-43. Cytosolic aggregation of TDP-43 is associated with disruption of normal cellular 
processes including protein degradation, response to oxidative stress and changes in 
mitochondrial bioenergetics (Stribl et al., 2014; Tashiro et al., 2012; Walker et al., 2013). 
Moreover, TDP-43 pathology is also associated with a loss of nuclear TDP-43, raising the 
possibility that TDP-43 pathology is mediated through a “loss of function” mechanism (Arai 
et al., 2006; Neumann et al., 2006). This concept is supported not only from the findings in 
this study but also from previous studies where silncing of TDP-43 result in cellular changes 
similar to those mediated by the introduction of TDP-43 mutants (Kabashi et al. 2010).  
Oxidative damage plays a central role in cell demis in a range of neurodegenerative 
conditions including ALS (Muyderman and Chen, 2014). Cells with a high energy demand, 
such as motor neurons, constantly produce the radical superoxide as a by-product of oxidative 
metabolism and depend heavily on cellular processes a  mediated by superoxide dismutase 
(SOD), catalase and glutathione (GSH)-dependent processes to minimize oxidative damage. 
SOD mediates the conversion of superoxide to hydrogen peroxide, which is then further 
detoxified by cytosolic catalase or GSH. In this context GSH directly detoxifies ROS in 
addition to its role as a substrate for several peroxidases (Dringen, 2000; Sims and 
Muyderman, 2010;Sims et al., 2004). We have previously demonstrated the importance of 
GSH in maintaining viability in several neural cell types, including those carrying ALS-















antioxidant directly results in mitochondrial dysfunction, ROS accumulation and cell death 
(Sims et al., 2004; Muyderman et al., 2007; Muyderman et al., 2004).  
 
In ALS, experimentally decreased GSH levels enhance dis ase progression in transgenic 
SOD1G93A mice (Vargas et al., 2011) and loss of total GSH content has been r ported in 
neuronal cell lines carrying the same mutation (Rizzardini et al., 2003). Moreover, decreased 
levels of oxidised GSH are seen in cerebrospinal fluid from ALS patients (Tohgi et al., 1999) 
and it was recently shown that this patient population also have reduced GSH content in 
motor cortex (Weiduschat et al., 2014). In addition, redox homeostasis is impaired in 
transgenic TDP-43 mice (Caccamo et al., 2013) and pharmacological depletion of GSH 
promotes cytosolic translocation of TDP-43 in cell ulture models (Iguchi et al., 2013).   
 
In the present study, we demonstrate that expression of mutant TDP-43, and the loss of 
endogenous TDP-43, produce disturbed production of GSH resulting in increased ROS levels 
and cell death which, more importantly, could be prvented by treatments that directly 
increases cellular GSH without the need for de novo synthesis. 
 
2. Materials and Methods 
2.1 Regents  
All chemicals were of analytical grade and obtained from Sigma (St. Louis, MO) unless 
stated otherwise. Glutathione monoethyl ester (GSHe) and ethacrynic acid (EA) were 
purchased from Chemodex (St Gallen, Switzerland). Tissue culture reagents, propidium 
iodide and calcein-AM were obtained from Invitrogen (San Diego, CA). NSC-34 cells were 
provided by Professor Neil Cashman (University of British Columbia, Vancouver, Canada). 















Serum, N2 supplement were purchased from GIBCO (Life Technologies, San Diego), while 
plastic and glass culture ware was obtained from Griene  (cellstar/Bio-One) purchased 
through SIGMA. 12mm Glass coverslips (12mm) were supplied by Thermo Fisher Scientific 
Inc. (Waltham, MA). 
 
2.2 Cell cultures 
Mouse NSC-34 motor neuron-like cell were grown in Dulbecco's Modified Eagle's Medium 
(DMEM), supplemented with 10% FBS, 1% L-glutamate and 1% mix of streptomycin and 
penicillin, until 80-90% confluent in a humidified atmosphere of 37°C in 5% CO2. Media 
was changed every third day and cells were passaged wh n confluent. Cells were subcultured 
every 3-4 days and not used beyond passage 24. In selected experiments, differentiation was 
induced by the removal of serum from the culture medium and the addition of 1% N2 
supplement media (DMEM, 1% FBS, 1% P/S, 1% L-glutamine and 1% N2 supplement. 
Differentiation was defined as the acquirement of amotor neuron-like morphology.  
 
2.3 Transfection of NSC-34 cells 
NSC-34 cells were transfected using nucleofection fllowing the instructions from the 
manufacturer with minor modifications. In short, semi-confluent cultures were trypsinized 
(0.05% (w/v) trypsin, 0.02 % EDTA in PBS pH 7.4 for 3 min at 37°C), pelleted by 
centrifugation at 90 g for 10 min, re-suspended in Hank’s HEPES-buffered salt solution 
(HBSS; in mM: 137 NaCl, 5.4 KCl, 0.41 MgSO4, 0.49 MgCl2, 1.26 CaCl2, 0.64 KH2PO4, 
3.0 NaHCO3, 5.5 glucose, and 20 HEPES, pH 7.4) and counted in a haemocytometer. Cells 
(2.5 x 106) were mixed with 100 µl of Nucleofector solution (Nucleofector Kit V, Lonza, 
Cologne, Germany) and transferred to the nucleofecti n uvette. Plasmid DNA was added to 















using program U-029. Immediately after nucleofection, the cells were re-suspended in full 
culture medium, re-counted and plated onto poly-D-lysine and collagen coated coverslips or 
in poly-L-lysine coated culture plates. Culture medium was replaced 4 hours after 
nucleofection and every second day thereafter.  
 
2.4 Plasmid construction 
Plasmids encoding for the TDP-43A315T mutation, human wild-type TDP-43 and the reporter 
gene mCherry only were prepared as previously described (Perera et al., 2014). Down-
regulation of TDP-43 expression was performed by transfection of NSC-34 cells with a 
custom made miRNA generating plasmid directed at TDP-43 expression at a concentration of 
2 µg/106 cells (BLOCK-iT™ Pol II miR RNAi Expression Vector with EmGFP under a 
human CMV promoter). Four constructs were made and v li ated by Western blot and semi-
quantified against GAPDH expression. Polymerase chain reaction was used to ensure 
insertion of the miRNA sequence, primers used were EmGFP forward (5’GGCATGGACGA 
GCTGTACAA 3’) and miRNA reverse (5’ACAAAGTGGGTTGATCTAGAG 3’). All 
plasmids were then sequenced and analysed under Vector NTI® software (Invitrogen, San 
Diego, USA). The construct producing the highest degre  of knock-down (74 ± 6%; n=5) was 
used in subsequent studies. The miRNA cassette for this construct contained the following 
sequence: 5'TTCAGCATTGGATATATGCACGTTTTGGCCACTGACTGACGTGCATA 
TCCAATA3'. Control plasmid contained the reporter gne only or a non-targeting miRNA 
(miRNAControl, Invitrogen).  
 
2.5 Immunocytochemistry 
Immunocytochemistry was performed using antibodies directed at the full length TDP-43 















serine 409/410 residues (pTDP-43; 1:500, Cosmos Bio, USA). Hoechst 33258 was used to 
visualize nuclei (1:5000, Invitrogen). In short, cells were washed in PBS and fixed for 20 min 
at 4˚C in 4% paraformaldehyde, washed in PBS and blocked for 30 min in PBS-BSA (1%)-
Triton X-100 (0.2%). Cells were then incubated with primary antibodies overnight at 4˚C 
followed by washes in blocking buffer and 45 min exposure to secondary antibodies. 
Confocal images were captured using a Leica SP5 Spectral Confocal Microscope (Leica 
Microsystems, Wetzlar, Germany) and processed using Ima eJ. Numbers of cells processed 
for image analysis were 250-350 per experiment. 
 
2.6 Cellular fractionation 
Nuclear and cytosolic fractions were produced using the Qproteome Cell Compartment Kit, 
(Cat#37502, QIAGEN Pty, Ltd., Hilden, Germany) following the manufacturer’s 
instructions. Histone H3 and GAPDH were used as markers for nuclear and cytosolic 
fractions respectively: while nuclear fractions contai ed no GAPDH, cytosolic fractions 
contained no Histone H3 as evaluated using Western Blotting (see Fig. 5b). 
2.7 Western blot 
Western blot was conducted using Nupage® Novex® 4-12% Bis-Tris gel with 1.0 mm x 10 
wells by Invitrogen ™ mounted on X-cell Surelock ® electrophoresis cell apparatus, and 
nitrocellulose membranes with 0.45mm pore size by Invitrogen, following protocols as 
prescribed by manufacturer.  Briefly, cells were washed in PBS, lysed in sodium dodecyl 
sulphate (SDS) and then heated at 70°C for 10 min before being subjected to a 4% SDS-
PAGE and transferred to a PDVF membrane. Membranes were incubated with primary 
antibodies against TDP-43 (1:250 Santa Cruz Biotechnologies, CA, USA), pTDP-43, (1:800, 
Cosmo Bio Co., LTD, Japan) and (GAPDH 1:2000, Applied Biosystems, Victoria, Australia) 















imaged for HRP chemiluminescence using a Fujifilm LAS4000 Imager. Densitometry was 
performed using FujiFilm Global Multigauge (R) software. Total protein was calculated 
using Carestream image analysis from the total protein transferred to the blotting paper and 
imaged with Bio-Rad EZ Doc Gel Imager and used for normalisation.  
2.8 RNA isolation and qPCR 
High-quality RNA was isolated using a phenol/chlorof m based method to separate RNA 
(Trizol) and further purification using column based isolation (RNeasy Mini Lit, Qiagen, 
Heiden, Germany). In short, cells were disintegrated and lysed using 1ml Trizol and a tissue 
lyser (Qiagen, Heiden, Germany, 3 min, 30 Hz). Chloroform (200 µl) was added to the 
solution, mixed for 30 s and after 3 min at room tep rature centrifuged (5 min, 4°C, 12,000 
rpm). The aqueous supernatant was used to isolate tt l RNA using a column based method 
including on-column DNAse digestion (RNeasy Mini Kit, Qiagen). Quantity and quality of 
the RNA were determined using a spectrophotometer (NanoDrop, Thermo Scientific, 
Australia) and a lab-on-chip system (Bioanalyzer, Agilent Technologies, Australia). Only 
RNA samples with RNA integrity numbers of higher than 7 were used for subsequent 
analysis. cDNA was synthesized using 1 µg of total RNA (iScript Reverse Transcriptase, 
BioRad, Australia) and used for subsequent qPCR using TaqMan and SybrGreen based 
qPCR. TaqMan primer assays were TDP43/Tardbp, (Mm0125750) and the reference gene 
Hprt (Mm01545399_m1), both Life Technologies. For SybrGreen qPCR we used mCherry, 
forward primer: CACTACGACGCTGAGGTCAA, reverse primer: 
TAGTCCTCGTTGTGGGAGGT; and the reference gene, forward primer: 
AGACGGCCGCATCTTCTTGTGC, reverse primer: GCCACTGCAAATGGCAGCCC. 
qPCR was performed using Power SYBR Green PCR master mix (Applied Biosystems) or 
TaqMan Gene Expression master mix (Applied Biosystem ) and a StepOnePlus cycler. 

















2.9 Assessing cell viability 
Cell survival was assessed immediately after nucleofecti n using trypan blue exclusion.  
Cells were resuspended in HBSS, containing 0.2% trypan blue (Sigma), incubated for 5 min 
and counted in a haemocytometer. Blue cells were considered non-viable whereas unstained 
cells were considered viable. Cell viability was also assessed at 24, 48 and 72 h after 
nucleofection using calcein-AM or propidium iodide (PI) staining. Briefly, cells were washed 
in serum free culture media and incubated for 15 min at 37°C with 5% CO2 with calcein 
green-AM (1 µM) or PI (25 µM). Hoechst 33258 (1:1000) was used to visualize chromatin 
condensation and apoptotic bodies if present. The proportion of PI positive or calcein green-
AM positive cells as well as cells with apoptotic-like features (chromatin condensation, 
neuritic blebbing and presence of apoptotic bodies) were assessed using standard 
fluorescence microscopy after Hoechst 33258 staining.  
 
2.10 Ethacrynic Acid and GSH monoethyl ester treatmnt 
EA (70µM) or ethanol vehicle control (Eth, 1%) was prepared and diluted in culture media 
(final ethanol concentration <0.25%). Cells were trea ed in flasks or on coverslips for 5 h. 
GSHe was diluted directly in full culture medium to a concentration of 5 mM. Control 
experiments were performed with vehicle only.  
 
2.11 Quantifying cellular GSH content 
A cellular GSH assay kit supplied by Abcam (ab138881) was used to determine total, 
reduced and oxidised GSH. Frozen cell pellet was first thawed and suspended in Tris-EDTA 
lysis buffer. Following suspension in lysis buffer, cells were sonicated for 2 min in a 10 sec 















min and the supernatant was collected. Using a microplate reader, total, reduced and oxidized 
GSH measurements were calculated according to manufacturer’s protocol. 
 
 
2.12 Detection of Reactive Oxygen Species 
To determine presence of reactive oxygen species produced by cells, a commercially 
available assay to detect ROS was used (Abcam - ab11385 ). To determine cellular ROS, 5 x 
104 of transfected cells were plated per well in a 96-well plate and allowed to proliferate for 3 
days. The assay was carried out according to manufacturer’s instructions 3 days post-
transfection.  
2.13 Protein determination 
Protein concentration assays were conducted using the DC BioRad protein assay kit (BioRad 
Laboratories, Hercules CA) following protocols as described by the manufacturer and 
absorbance read at 750 nm using a Perkin Elmer Victor ® X4 Multilabel Plate Reader. 
 
2.13 Statistical analyses  
Results are presented as mean ± SD. Each experimental condition was tested on cultures 
obtained from at least 3 independent passages of cells. Individual values were determined as 
the average of results obtained from at least three id ntically treated culture plates from the 
same experimental day and compared to control-treated sister cultures. Statistical analyses 
were performed on raw data by Student t-test or by one-way ANOVA followed by Student-
Newman-Keuls test. P values <0.05 were considered significant. 
 
3. Results 















NSC-34 cells had an average total GSH concentration of 30 ± 6 nmol/mg protein with a 
reduced (GSH) to oxidised  glutathione (GSSG) ratio of 46 (n=5: Figure 1A). Exposure to 
EA (70µM, 5 h) significantly reduced total GSH conte t to 7.3 ± 2.8 nmol/mg which was 
associated with a decrease in GSH:GSSG ratio from 46 to 9 (Fig. 1A). Vehicle treatment 
(Eth; 1%, 5 hrs) alone did not significantly alter GSH content or the GSH: GSSG ratio (Fig. 
1A). Consistent with these results, EA treatment resultd in a significant increase in cellular 
ROS content (Fig. 1B), but did not result in impaired cell viability at this time point (5 hr: 
p>0.05 data not shown).  
 
3.2 EA-mediated depletion of GSH results in redistribution of endogenous nuclear TDP-43 
and in the expression of pTDP-43.  
 
While non-treated NSC-34 cells showed primarily nuclear localization of TDP-43 and low 
levels of pTDP-43 (Fig.  2A), the majority of EA-treated cells displayed a cytoplasmic 
distribution of TDP-43 associated with nuclear clearance of the protein (Fig. 2B) together 
with a significant increase in extra nuclear pTDP-43 immunoreactivity (Fig. 2C). To verify 
that EA had no direct effect on TDP-43 distribution cells were co-incubated with EA together 
with the cell permeable GSHe (5 mM), which counteracted EA-mediated GSH depletion 
(Fig. 1A), prevented increased ROS production (Fig. 1B) and cytoplasmic re-distribution and 
nuclear clearance of TDP-43 in these cells. GSHe was also assessed for cytotoxicity using 
calcein/PI as described under Methods; data demonstrated that exposure of normal NSC-34 
cells to concentrations not exceeding 7.5 mM did not result in decreased cell viability (data 
not shown). Thus, 5 mM GSHe was used throughout the remaining study.  
 















To test the impact of ALS-linked mutant TDP-43 on GSH expression, NSC-34 cells were 
transfected with the mCherry-tagged human TDP-43A315T mutation, the human wild-type 
TDP-43 or with a control plasmid encoding for the rporter gene mCherry using 
nucleofection. This procedure resulted in transgene xpression within 24 h reaching a 
maximum transfection efficiency of 56 ± 9%, 67 ± 11% and 69 ± 7 % at 72 hr post-
transfection, respectively (n=3). Cell death, assesed based on the ability of these cells to 
retain calcein fluorescence, nuclear incorporation of propidium iodide or the presence of 
apoptotic-like morphology changes (as described earlier), at 24, 48 or 72 h after transfection 
was not significantly different in cultures nucleofcted with either wild-type TDP-43 or with 
the control plasmid compared with non-nucleofected cultures (n=5: p>0.05), but higher in 
cells expressing the TDP-43 mutant (Fig. 3). qPCR showed no significant differences in 
expression levels of mutant versus wild-type TDP-43 (n=3; ANOVA; p>0.05).3.4 Cytosolic 
redistribution of TDP-43 in cells expressing the A315T mutant 
Transfection of NSC-34 cells with TDP-43A315T resulted in cytosolic redistribution of TDP-
43 in 21 ± 5 % of the cells, while cells expressing the reporter gene only showed exclusive 
nuclear localization of TDP-43 (Fig. 4A andB; n=5). Nuclear TDP-43 levels were also 
quantified using Western Blot after cellular fractionation. In cells expressing TDP-43A315T, 
there was a significant decrease in nuclear TDP-43 expression compared to control (Fig. 5A). 
Control experiments verified the purity of these fractions using Histone 3 and GAPDH as 
markers for nuclear and cytosolic fractions respectiv ly (figure 5b). In these cells the 
cytosolic fraction contained 6 ± 2 % of total TDP-43 content while the nuclear fraction 
contained 94 ± 5% compared to a > 65% decrease in nuclear TDP-43 content in cells carrying 
the mutant (Fig. 5A and B).  















TDP-43A315T expressing cells had a total GSH concentration of 5 ± 1 nmol/mg protein (n=5) 
representing a >80% decrease compared to the cells transfected with vector alone where then 
level was 24 ± 4 nmol/mg protein. Values for cells xpressing wild-type TDP-43 were 28 ± 6 
nmol/mg protein relative to non-transfected cells at 31 ± 3 nmol/mg protein (n=3). GSSG 
accounted for 15% of total GSH concentration in A315T transfected cells compared to less 
than 3% in non-transfected cells and in cells transfected with the control plasmids (Fig. 1A). 
The GSH: GSSG ratio in A315T transfected cells was 6.25 compared to that of control 
transfected cells of 55. As for EA-treated cells, the introduction of the TDP-43A315T mutation, 
but not wild-type TDP-43, resulted in significantly increased ROS levels as assessed 3 days 
post transfection compared to that of control cells (Fig. 1B). Depletion of GSH and increased 
levels of ROS content were closely associated with a decrease in cell viability in cells 
carrying mutant TDP-43 (Fig. 3). Furthermore, based on inconsistencies in GAPDH 
expression used as a loading control, we also assessed if TDP-43A315T affected the expression 
of this key enzyme in glycolysis. Results show thatere was a five-fold decrease in GAPDH 
expression in cells carrying the TDP-43A315T mutant compared to control (Fig. 6). Hence, 
throughout this study, Western Blot results were normalised relative to total protein in the 
sample after using stain-free gels processed by Carestream image analysis and Bio-Rad EZ 
Doc Gel Imager. 
3.6 Restoring cellular GSH content prevents TDP-43 pathology 
Next, we addressed whether increasing availability of GSH in mutant TDP-43A315T 
transfected cells reduced TDP-43 pathology. NSC-34 cells transfected with TDP-43A315T or 
with the control vector were treated with 5 mM GSHe starting 3 h post transfection. The 
results demonstrated that early restoration of GSH content prevented nuclear loss of TDP-43 
(Fig. 4 and 5), reducing both ROS content (Fig. 1B)and cell death (Fig. 3). Moreover, GSHe 















Next, we investigated plausible mechanisms behind GSH depletion in cells carrying the 
A315T mutation by determining the expression of GSH-related proteins using Western blot. 
While there were no significant changes in GSH reductase or GSH peroxidase (data not 
shown), the results showed a several-fold decrease in the expression of the regulatory subunit 
of GCLM (Fig. 7) indicative of a severely impaired ability to synthesise GSH. 
 
 
 3.7 GSH depletion in TDP-43 pathology is mediated through a loss of function mechanism. 
To establish if a loss of TDP-43 expression would result in similar disturbances to GSH 
homeostasis we silenced endogenous TDP-43 expression in untreated NSC-34 cells (Fig. 8). 
Down-regulation of TDP-43 expression was performed by transfection of NSC-34 cells with 
1 µg/106 cells of four custom-made plasmids generating micro RNA (miRNA: 508-511) 
directed against TDP-43 mRNA (BLOCK-iT™ Pol II miR NAi Expression Vector with 
EmGFP under a human CMV promoter). Controls were treated with a plasmid generating a 
non-targeting miRNA (miRNAControl, Invitrogen) and changes in TDP-43 expression were 
determined by immunoblotting. Silencing of TDP-43 expression using the miRNA construct 
with most pronounced effect resulted in an overall 50% decrease in protein expression in 
transfected cultures as assessed using western blot. This decrease corresponded to a near total 
loss of TDP-43 in individual cells expressing the construct (Fig. 8). Silencing of TDP-43 
resulted in a significant decrease of GSH content (Fig. 9), several-fold increase in ROS 
production, and substantially increased cell death (Fig. 1B and 2). However, in contrast to 
cells expressing the TDP-43A315T mutation, cell death were not preserved in these clls after 
treatment with GSHe (Fig. 3), suggesting that a totl depletion of TDP-43 is lethal in NSC-34 
cells involving additional mechanisms in addition t ROS accumulation. Still, these data are 















GSH production, increased ROS production potentially leading to the aggravation of TDP-43 
pathology. 
4. Discussion 
The present study has identified conditions under which GSH in neuronal cells expressing 
TDP-43A315T mutant is essentially depleted, resulting in increased ROS production, TDP-43 
nuclear-to-cytosolic redistribution and cell death. T is study provides the first direct evidence 
for a critical role of cellular GSH in preserving neuronal viability in TDP-43 pathology. Loss 
of GSH as a result of the presence of this mutation, or in response to the depletion of 
endogenous TDP-43, resulted in increased intracellular ROS levels, cell death and cytosolic 
redistribution of TDP-43 whereas protection against mutant TDP-43-mediated cytotoxicity 
was provided by restoration of intracellular GSH using GSHe. Overexpression of human 
wild-type TDP-43 did not result in any changes in GSH content or in ROS production. This is 
consistent with a recent study demonstrating that exclusive overexpression of wild-type TDP-
43 in transgenic mice does not result in an ALS-like phenotype (Mitchell et al., 2015). 
Our results also indicated that dysregulation of TDP-43 may result from impaired expression 
of theGCLM, responsible for GSH synthesis, subsequent GSH depletion and increase in ROS 
levels. Although this evidence does not rule out other molecular mechanisms, a loss of  γ-
glutamylcysteine ligase activity may explain the disappointing results in previous attempts 
aimed at enhancing antioxidant defence processes by providing GSH precursors in ALS 
(Andreassen et al., 2000). Other plausible explanations include a r duction in the activity of 
the sodium-dependent excitatory amino acid transporter 1 that is responsible for GSH 
precursor uptake into these cells. This issue was not addressed in the current study but is the 
subject of ongoing investigations. In theory, it is al o possible that cellular GSH content can 















mechanism preventing accumulation of this potentially oxidising agent (Dringen and 
Hirrlinger, 2003). However this was not supported by the results in the current study.  
Oxidative stress, like protein aggregation, constitutes a key pathogenic mechanism of cell 
death in ALS. In support of this standpoint, post-mortem analyses consistently demonstrate 
oxidative damage and markers of oxidative damage are increased in plasma, urine and CSF 
of ALS patients (Muyderman and Chen, 2014; D'Amico et al., 2013). In addition,  
experimentally increased oxidative stress load accelerat s disease progress in animal models 
of ALS (D'Amico et al., 2013).  
A majority of ALS cases (>95%) are associated with cytosolic inclusions containing TDP-43 
and the relocation of this protein from the nuclei to the cytoplasm, changes that are likely to 
make a significant contribution to cellular dysfunction and subsequent pathology. In addition 
to changes in protein folding and degradation, cytosolic accumulation of TDP-43 causes 
oxidative stress and mitochondrial dysfunction (vide supra). Given that GSH plays a critical 
role in cellular defence against oxidative stress in various neurodegenerative conditions, it is 
surprising that its role in ALS remains poorly understood. Especially considering that redox-
mediated signalling previously has been linked to the regulation of TDP-43 and that oxidative 
stress promotes TDP-43 cross-linking via cysteine oxidation and disulphide bond formation 
leading to decreased TDP-43 solubility (Cohen et al., 2012). 
In this study we reproduced the finding of a previous study demonstrating that depletion of 
GSH results in increased cytosolic aggregation of TDP-43 (Iguchi et al., 2013) and expanded 
on these studies to demonstrate that the content of GSH in cells carrying mutant TDP-43 is 
not optimal and that restoring this antioxidant pool, using a treatment that does not require 















Treatment with GSHe rapidly restored intracellular GSH levels and prevented TDP-43 
pathology in NSC-34 cells carrying TPD-43A315T. In contrast to GSH, which is poorly 
transported into cells and do not pass the blood brain barrier, GSHe is cell-permeable, readily 
de-esterified by intracellular esterases and rapidly ncreases intracellular GSH content 
(Wadey et al., 2009; Muyderman et al., 2007) We have previously demonstrated the 
beneficial effects of GSHe of increasing glutathione content in both in vitro and in vivo 
models (Muyderman et al., 2007; Muyderman et al., 2004). We have alsosh wn that such 
treatment significantly improves cellular resistance against oxidative stress and that the 
depletion of this antioxidant directly correlates with increased susceptibility to oxidative 
damage. Moreover, pre-symptomatic administration of GSHe has recently proven somewhat 
beneficial in increasing lifespan in the SOD-1G93A, albeit demonstrating a very modest effect 
of approximately 10% (Winkler et al., 2014). However, in this study, GSHe was given as a 
daily intraperitoneal injection and GSH levels in spinal cord or brain were not determined 
making it highly plausible that the major increase in cellular GSH was contained to the 
abdominal cavity. Nevertheless it highlights the ned for anti-oxidant treatment in ALS and 
indicates the central role of GSH in this process. Thus, the characterization of TDP-43-
mediated GSH depletion in our present study complements these data and has generated 
several unique insights into the properties of thiskey antioxidant in TDP-43 pathology. Most 
notably that mutant TDP-43 as well as silencing of endogenous TDP-43, depletes 
intracellular GSH and that its replacement provides overall cellular protection. In this context, 
a few previous studies also suggest that TDP-43 pathologies are associated with an imbalance 
in antioxidant redox buffering systems, with mitochndrial dysfunction most likely 
responsible for the increase in ROS production seen in GSH depleted cells (Caccamo et al., 
2013; Iguchi et al., 2012). In addition, alterations of cellular redox state may lead to 















functions by oxidative stress may result in protein aggregation as seen in TDP-43 pathology. 
This evidence is in line with our current results showing that restoring cellular GSH content 
prevents cytosolic redistribution and nuclear clearance of TDP-43. In support of this concept, 
ALS cases show proteasomal impairment associated with an increase in oxidative stress 
markers (Ilieva et al., 2007; Kim et al., 2009; Neutzner et al., 2012; Tashiro et al., 2012) and 
increased ROS production is intimately associated to impairment of the removal of 
ubiquitinated proteins (Cohen et al. 2012). Moreover, experimentally decreased GSH 
accelerates disease progression in the SOD1G93A transgenic (Vargas et al., 2011) and loss of 
total GSH content in motor neurons has been reported in cell lines carrying the same 
mutation (Rizzardini et al., 2003).Additionally, reduced levels of GSSG have been reported 
in cerebrospinal fluid from ALS patients (Tohgi et al., 1999) and we have recently shown a 
reduction in mitochondrial GSH in mSOD1G93A expressing NSC-34 cells (Muyderman et al., 
2009).  
In addressing the mechanisms underlying the reduction in cellular GSH, we observed a 
several-fold decrease in the regulatory subunit of he rate limiting enzyme responsible for 
GSH synthesis in cells expressing mutant TDP-43A315T. This result is most likely the major 
reason for the observed depletion of cellular GSH and increase in ROS content in these cells 
and is supported from previous studies in which genetic deletion of GCLM resulted in 
decreased GSH content and increased susceptibility to oxidative stress (Botta et al., 2008; 
Mohar et al., 2009).  
Finally we demonstrated that silencing of endogenous TDP-43 produced similar changes to 
those produced by the introduction of mutant TDP-43 in regard to GSH depletion and cellular 
ROS content. This finding implies additionally that TDP-43 pathology, at least to some 
extent, is mediated through a “loss of action” mechanism consistent with previous studies 















neurodegeneration with a phenotype similar to those of animal models of ALS (Yang et al., 
2014). In contrast to cells expressing mutant TDP-43, GSHe treatment did not salvage cells 
depleted of TDP-43. This is not surprising as a totl loss of TDP-43 function would result in 
severe cellular dysfunction in which GSH depletion and ROS accumulation would constitute 
minor effects. However, the results highlight the role of TDP-43 in redox regulation and GSH 
synthesis.  
 
In summary, this study demonstrates that normal TDP-43 function may be regulated via 
redox mechanisms and that oxidative stress is central to TDP-43 proteinopathy, most likely 
dependent on impaired synthesis of GSH. We propose that a loss of TDP-43 function leads to 
the depletion of GSH and thereby further aggravates pathological cytosolic protein 
aggregation and impairment of cell function. Together, our data strongly indicate that 
treatments directly aimed at restoring intracellular GSH will attenuate formation of cytosolic 
TDP-43 aggregates and reduce MN death in TDP-43-mediated ALS. Thus, intra-CSF 
administration of such restorative agents would constitute a feasible approach to increase MN 
viability and slow disease progression if translated to human subjects.  
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Figure legends  
Fig. 1. Analyses of GSH (A) and oxidative stress (B) in motor neuronal NSC-34 cells. Values 
are mean ± S.D. (full details in Materials and methods). (A) Total, reduced and oxidized 
(GSSG) GSH expression in NSC-34 cells after treatmen  with; from left to right 70 µM EA 
for 5 hours, EA-treated cells treated with 5 mM GSHe, 1% ethanol (Eth vehicle) cells 
overexpressing the human wild-type TDP-43 (Wt), cells transfected with the TDP-43A315T 
mutation, cells transfected with the TDP-43A315T mutation and treated with 5 mM GSHe for 
72 h, cells transfected with a control plasmid encoding for the reporter gene mCherry only 
and non-treated cells (NT). *** p<0.001 ANOVA with SNK, n=5. (B) Cellular content of 
reactive oxygen species (ROS) in cells identically treated as in (A) with the addition of cells 
depleted of TDP-43 (miRNA) and the corresponding miRNA scrambled control 72 h post-
transfection. *** p< 0.001, ANOVA with SNK, n=5.  
Fig. 2. Confocal micrographs showing extra nuclear localization of TDP-43 and pTDP-43 
after 5 hours of EA treatment (70 µM EA) causing GSH depletion. Left: TDP-43 and pTDP-
43 immunoreactivity (green); Middle: Nuclear stain DAPI (blue); and Right: the 
superimposed picture. (A) Full length TDP-43 and pTDP-43 immunoreactivity (green) in 
untreated NSC-34 cells. (B) Full length TDP-43 expression in cells depleted of GSH after EA 
treatment (arrows indicate extra nuclear TDP-43 localization). (C) Expression of pTDP-43 in 
NSC-34 cells depleted of GSH after GSH depletion. Scale bars 25 µm. One out of 5 
representative experiments.   
 
Fig. 3. Cell viability in NSC-34 cells expressing TDP-43A315T, the mCherry control plasmid, 
miRNA or the miRNA scrambled control 24, 48 and 72 h after transfection and with or 
without GSHe treatment. GSHe treatment (5 mM) was initiated 3h post-transfection and this 













details in Materials and methods). GSHe treatment significantly reduced cell death in cells 
expressing the A315T mutation (***p<0.001) but not in cells depleted of TDP-43 compared 
to the mCherry control and mutant cells treated with GSHe (### p<0.001compared to 
miRNA negative control). ANOVA with SNK, n=5. 
Fig. 4. Confocal micrographs showing the redistribution of TDP-43 (green) in motor 
neuronal NSC-34 cells expressing the A315T mutant. Nuclei were stained with DAPI and 
appear blue. Arrows indicate extra nuclear TDP-43 localization (n=5). (A). Cytosolic 
redistribution of TDP-43 (green) in cells transfected with TDP-43A315T (mCherry; red). (B) 
Cells expressing the reporter gene only (mCherry; red). (C) Normalization of TDP-43 
immunoreactivity (green) in cells transfected with the A315T mutation (red) and treated with 
5 mM GSHe (72h). Scale bars 25 µm. 
Fig. 5. Quantitative analyses of nuclear expression of TDP-43 compared to total nuclear 
protein as measured after cellular fractionation and quantitative Western immunoblotting 
(using Carestream image analysis from the total protein transferred to the blotting paper and 
imaged with Bio-Rad EZ Doc Gel Imager and used for n malisation, thus no reference 
protein needed).  Values are mean ± S.D.  (A) NSC-34 cells transfected with the TDP-43A315T 
mutation, cells expressing TDP-43A315T and treated with GSHe, and cells transfected with the 
reporter gene only (Cherry) or non-transfected cells (NT). Insert: Corresponding gel image. 
p19-22 refers to passage number of the NSC-34 cells. *** p<0.001, ANOVA with SNK 
posthoc test, n=6. (B) Typical Western blot demonstrating the purity of nuclear and cytosolic 
fractions using Histone 3 (H3) and GAPDH, respectively, as markers in untreated cells (left) 
and in cells expressing the TDP-43A315T mutant.  
Fig. 6. Effect of the TDP-43A315T mutation on key glycolytic enzyme GAPDH. Values are 













in cells transfected with the TDP-43 mutation A315T, cells expressing mutant TDP-43 and 
treated with GSHe, cells transfected with the reporter gene only (Cherry) and in non-
transfected cells (NT). Insert: Corresponding gel image. p19-22 refers to passage number of 
the NSC-34 cells. *** p<0.001, ANOVA with SNK posthoc test, n=6. 
Fig. 7. Changes in expression of GCLM. Western immunoblotting of GCLM expression in 
cells transfected with the TDP-43A315T mutation compared to cells transfected with the 
control plasmid only. Values are mean ± S.D. (full details in Materials and methods). Insert: 
corresponding gel image. p19-22 refers to passage number of the NSC-34 cells. *** 
p<0.0001, Student t-test, n=6. 
Fig. 8. TDP-expression after silencing using miRNA constructs (508-511). Values are mean 
± S.D. (full details in Materials and methods). TDP-43 expression relative to protein content, 
*** p<0.001, ANOVA with SNK posthoc test, n=5. Insert: corresponding gel image. Results 
are typical for one out of five experiments.  
Fig. 9. GSH content and endogenous TDP-43 expression. Total cellular GSH content after 
miRNA-mediated silencing of TDP-43 expression. Values are mean ± S.D. (full details in 


















































































































































• MND causing mutations in the TDP-43 gene result in non-functioning glutathione producing 
enzymes 
• TDP-43/MND-causing mutations cause glutathione depletion 
• Preventing, or restoring, glutathione content prevent cell death in motor neuronal NSC-34 
cells expressing TDP-43 mutations causing motor neuron disease  
 
 
